Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This adds Blueprint’s medicine for systemic mastocytosis (SM), a rare immunology disease, to Sanofi’s growing immunology pipeline. The acquisition includes Ayvakit/Ayvakyt (avapritinib), which is the only approved medicine for advanced and indolent SM. Additionally, Sanofi will […]
The post Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases appeared first on Pharmafile.
